Researchers at Stanford Medicine have identified a possible biological mechanism behind the rare cases of myocarditis following mRNA COVID-19 vaccination. The condition remains uncommon and generally mild, with most patients recovering fully.
In a comparative study, the team found elevated levels of two immune signaling molecules—CXCL10 and interferon-gamma—in individuals who developed post-vaccine heart inflammation. Specifically, certain immune cells produced excessive CXCL10, which then stimulated T cells to boost interferon-gamma activity, amplifying inflammatory signals that may lead to myocarditis in rare cases. Laboratory and animal experiments showed that blocking these pathways reduced inflammation without compromising the broader immune response, pointing to potential future treatments or preventive strategies. The researchers emphasize that the study aims to enhance vaccine safety by explaining uncommon side effects, not to undermine the overall benefits of vaccination—especially given that COVID-19 infection itself poses a greater risk of heart inflammation than the vaccine. Health experts continue to affirm that mRNA vaccines are safe and effective for the vast majority of people.
